Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ATAC-seq and ChIP-seq studies after Sirt6 inactivation in MuSCs/mESCs

ABSTRACT: ATAC-seq and ChIP-seq studies after Sirt6 inactivation in MuSCs/mESCs

PROVIDER: PRJNA706934 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13863549_1.fastq.gz	Fastqsanger.gz
	SRR13863549_2.fastq.gz	Fastqsanger.gz
	SRR13863550_1.fastq.gz	Fastqsanger.gz
	SRR13863550_2.fastq.gz	Fastqsanger.gz
	SRR13863551_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 22

Similar Datasets

ATAC-seq and ChIP-seq studies after Sirt6 inactivation in MuSCs/mESCs

Project description:ATAC-seq and ChIP-seq studies after Sirt6 inactivation in MuSCs/mESCs

| PRJNA706934 | ENA

Genome-wide H3K56ac profiling after Sirt6 inactivation in MuSCs [ChIP-seq]

Project description:Sirt6, the NAD+-dependent deacetylase, has been described to deacetylate H3K9, H3K18, and H3K56. However, analysis of the acetylation status revealed that loss of Sirt6 caused a massive increase of histone H3K56ac levels but no detectable change of histone H3K9ac and H3K18ac, indicating that SIRT6 is the dominant deacetylase for H3K56ac in muscle stem cells (MuSCs). Further, we investigate genome-wide H3K56ac profiling in the absence of Sirt6 in MuSCs and mouse embryonic stem cells (mESCs) using high throughput sequencing (ChIP-seq).

2022-05-13 | GSE168330 | GEO

Genome-wide H3K56ac profiling after Sirt6 knockdown in mESCs [ChIP-seq]

2022-05-13 | GSE168331 | GEO

Genome-wide H3K56ac profiling after Sirt6 inactivation in MuSCs [ChIP-seq]

Project description:Genome-wide H3K56ac profiling after Sirt6 inactivation in MuSCs [ChIP-seq]

| PRJNA706938 | ENA

Genome-wide DNA accessibility maps after Sirt6 inactivation in muscle stem cells [ATAC-seq]

Project description:Sirt6, the NAD+-dependent deacetylase, has been described to deacetylate H3K9, H3K18, and H3K56. However, analysis of the acetylation status revealed that loss of Sirt6 caused a massive increase of histone H3K56ac levels but no detectable change of histone H3K9ac and H3K18ac, indicating that SIRT6 is the dominant deacetylase for H3K56ac in muscle stem cells (MuSCs). Further, we investigate genome transposase-accessible chromatin in the absence of Sirt6 in MuSCs using high throughput sequencing (ATAC-seq).

2022-05-13 | GSE168329 | GEO

ATAC-seq and ChIP-seq studies after Sirt6 inactivation in MuSCs/mESCs

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-05-13 | GSE168332 | GEO

Transcriptome profiling of muscle stem cells from control, mdx and Sirt6 knockout on mdx background mice

Project description:In this study, Pax7-Cre mediated inactivation of Sirt6 in mdx mice resulted in profound improvement of the mdx phenotype at the functional level. To study the underlying molecular mechanisms we performed RNA-seq of MuSCs from control, mdx and Sirt6mKO/mdx mice.

2022-05-12 | GSE168983 | GEO

SIRT6 suppresses pancreatic cancer through control of Lin28b [ChIP-seq]

Project description:Chromatin remodeling proteins are frequently dysregulated in human cancer, yet little is known about how they control tumorigenesis. Here, we uncover an epigenetic program mediated by the NAD+-dependent histone deacetylase Sirtuin 6 (SIRT6) that is critical for suppression of pancreatic ductal adenocarcinoma (PDAC), one of the most lethal malignancies. SIRT6 inactivation accelerates PDAC progression and metastasis via upregulation of Lin28b, a negative regulator of the let-7 microRNA. SIRT6 loss results in histone hyperacetylation at the Lin28b promoter, Myc recruitment, and pronounced induction of Lin28b and downstream let-7 target genes, HMGA2, IGF2BP1 and IGF2BP3. This epigenetic program defines a distinct subset representing 30-40% of human PDAC, characterized by poor prognosis and an exquisite dependence on Lin28b for tumor growth. Thus, we identify SIRT6 as an important PDAC tumor suppressor, and uncover the Lin28b pathway as a potential therapeutic target in a molecularlydefined PDAC subset. ChIP-Seq experiments to examine H3K56ac histone modifications in murine PDAC cells that are Sirt6 wild type (WT), Sirt6 knock-out (KO), and Sirt6 KO cells engineered to express Sirt6 WT (Sirt6 KO + Sirt6 WT Restored).

2016-04-01 | E-GEOD-79503 | biostudies-arrayexpress

Inactivation of Sirt6 ameliorates muscular dystrophy in mdx mice by releasing suppression of utrophin expression

Project description:In this study, Pax7-Cre mediated inactivation of Sirt6 in mdx mice resulted in profound improvement of the mdx phenotype at the functional level. To study the underlying molecular mechanisms and identify specific Sirt6 targets irrespectively to mdx mutation, we performed RNA-seq of freshly isolated muscle stem cells from control and Sirt6mKO mice.

2022-05-12 | GSE199487 | GEO

Genome-wide H3K56ac profiling after Sirt6 knockdown in mESCs [ChIP-seq]

Project description:Genome-wide H3K56ac profiling after Sirt6 knockdown in mESCs [ChIP-seq]

| PRJNA706939 | ENA